Trial Profile
A Phase IIa Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study to Investigate the Clinical Efficacy, Safety, and Tolerability of Nemiralisib (GSK2269557) in Symptomatic COPD Participants with a History of Exacerbations
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Nemiralisib (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Proof of concept; Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 16 May 2019 This trial has been discontinued in Netherlands
- 18 Apr 2019 This trial has been completed in Poland, according to European Clinical Trials Database.
- 30 Jan 2019 This trial has been completed in Sweden.